Nul, a UK-based HealthTech startup constructing a supported alcohol discount platform that provides entry to medical care and prescription treatment, at present introduced that it has raised practically €840k ($1 million) in Seed funding to help UK launch, staff enlargement, and worldwide development plans.
The spherical was led by dmg ventures, the enterprise arm of Each day Mail and Common Belief, and BYVP, together with a bunch of angel buyers with backgrounds in know-how, healthcare, and client manufacturers.
Matus Maar, founder and CEO of Nul, mentioned, “Alcohol discount is without doubt one of the largest and least modernised areas in healthcare. Telehealth and on-line pharmacy platforms have reworked classes like weight reduction and psychological well being, but alcohol has been left behind regardless of the size of the issue. Nul is about making evidence-based therapy accessible, discreet and appropriate with actual life.”
Based by Maar, co-founder of Talis Capital, Nul is constructing a telehealth platform that mixes medical care and prescription treatment with digital pathways and behavioural help to assist individuals scale back their alcohol consumption.
In accordance with Nul, its core programme is constructed round naltrexone, an FDA-approved treatment to deal with opioid use dysfunction (OUD) in addition to alcohol use dysfunction (AUD). Much like GLP1, naltrexone performs on reward pathways and is used to cut back alcohol cravings. Nul claims that its programme is delivered by way of a totally distant, subscription-based service that features digital session, ongoing medical help, and structured digital help primarily based on The Sinclair Methodology, which medical research have reported to have successful fee of as much as 78% (Sinclair, John – Medical Research, 2001). Its companions embody Blueco Healthcare and Thriva.
Rachel Muzyczka, Associate at dmg ventures, mentioned, “Nul’s mission to empower people to take management of their relationship with alcohol is each well timed and transformative. Their strategy just isn’t solely progressive however deeply aligned with the rising demand for more healthy existence. We see great potential of their strategy and the market they’re serving.”
With the Seed funding, the corporate will help a full UK business launch, increase its medical and product groups, purchase prospects at scale, and put together for worldwide enlargement, together with the US.
In parallel with the Seed spherical, Nul says it plans to launch a crowdfunding campaign on Republic Europe later this week, enabling retail buyers to take part within the spherical and help the firm’s subsequent section of development. It plans to lift additional capital in 2026 because it scales within the UK and enters new markets
Nul notes that it launched a UK check section in summer season 2025 and has onboarded greater than 120 paying prospects. It reported reaching an annualised income run-rate of practically €344k (over £300,000) inside its first few months, pushed largely by natural demand and phrase of mouth. The startup plans to lift additional capital in 2026 because it scales within the UK and enters new markets.
